Back

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Chronic Heart Failure ePosters Comorbidities ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Atsushi Tanaka

Saga University, Saga (Japan)

274 More presentations in this session

Presentation thumbnail
Increased myocardial fat supply improves cardiac energetics and function in heart failure
Doctor W. Watson (Cambridge, GB)
Abstract Slides
Presentation thumbnail
Cardiac aging is regulated by autophagic disorder mediated by chronic inflammation via the Rubicon/NOX4 pathway.
Doctor T. Kamihara (Obu, JP)
Abstract Slides
Presentation thumbnail
Participants with diabetes have less augmentation in cardiac function and energetics in response to increased supply of fatty acid
Doctor P. Green (Hobart, AU)
Abstract Slides
Presentation thumbnail
Impaired high-density lipoprotein function in patients with heart failure
Ms L. Emmens (Groningen, NL)
Abstract Slides
Presentation thumbnail
The comparison of clinical significance between atrial and ventricular structural remodeling in patients with heart failure with preserved ejection fraction - insights from PURSUIT-HFpEF registry
Doctor M. Okada (Osaka, JP)
Abstract Slides

Access the full session

Session thumbnail
Chronic Heart Failure ePosters

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
Therapeutic implications of the cardio-renal-metabolic multimorbidity
thumbnail
Congress Presentation
Obesity and inactivity cluster is the strongest predictor of incident heart failure in a population-based study
thumbnail
Congress Presentation
Defining patterns of comorbidity accrual before and after the diagnosis of heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources